STADA Expands its Specialty Footprint with the Acquisition of Lobsor Pharmaceuticals

 STADA Expands its Specialty Footprint with the Acquisition of Lobsor Pharmaceuticals

STADA Expands its Specialty Footprint with the Acquisition of Lobsor Pharmaceutical

Shots:  

  • STADA acquires Lobsar and its innovative therapy to foster its footprints in specialty pharmaceuticals. The acquisition complements STADA’s portfolio and expertise in the treatment of late-stage Parkinson’s disease
  • With the acquisition, STADA gain rights to a triple fixed combination (levodopa/carbidopa/ entacapone) delivered via modern pump technology, already launched in Nordic countries
  • Levodopa, carbidopa and entacapone infusion therapy is inserted in the small intestine through a discreet, wearable pump. The infusion is approved in Sweden, Denmark, Norway, and Finland, while STADA is currently submitting approval applications to launch the therapy in multiple EU markets

Click here ­to­ read full press release/ article | Ref: STADA | Image: S

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post